Global Plasma Protease C1-inhibitor Treatment Market
Overview:
Hereditary angioedema is characterized by low levels of functional C1 esterase inhibitor protein and is an autosomal disease. Patients affected with HAE are treated using purified concentrate of C1 esterase inhibitors. Various plasma protease C1-inhibitors like Firazyr, Berinet, Cinryze and Kalbitor, these are approved for treating prophylactic and acute attack of hereditary angioedema. C1-inhibitor are part of the serine protease inhibitors family. C1-inhibitors help in controlling the activation of the C1 complex as they form an inactive stoichiometric complex with the C1s proteases. They also play a vital role in blood coagulation, generation of kinins, complement activation and fibrinolysis.
Global plasma protease c1-inhibitor treatment market, is forecast to be valued at US$ 3,289.5 million in 2020 over the forecast period.
Click Here to Get a Sample Copy (Exclusive Offer: Up to 30% Discount for A Limited Time) @ https://www.coherentmarketinsights.com/insight/request-sample/4262
Drivers:
Rising product approvals is anticipated to propel growth of the global plasma protease C1-inhibitor treatment market over forecast period. For instance, CSL Behring gained approval from the U.S. FDA for their C1 Esterase Inhibitor Subcutaneous for humans in June 2017. This is the only therapy which is indicated for preventing hereditary angioedema attacks in adult and adolescent patients.
Furthermore, key biopharmaceutical companies are focusing on developing C1-inhibitor therapies or drugs, which is estimated to augment growth of the global plasma protease C1-inhibitor treatment market over the forecast period.
For instance, phase 2 clinical studies of IONIS-PKK-LRx were initiated by Ionis Pharmaceuticals, Inc. in October 31, 2019, for examining the safety, tolerability and efficacyin patients suffering hereditary angioedema type 1, type 2 or HAE with normal C1-inhibitor. This study will also evaluate the results of other biomarkers and their effect on IONIS-PKK-LRx on plasma prekallikrein.
Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables& Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-pdf/4262
Impact of COVID-19:
- Covid-19 led to hampering the growth of healthcare industry as it was transmitted around the globe, resulting in increased number of deaths.
- The WHO announced COVID-19 as a pandemic in March 2020, and also suggested strict measures for minimizing the transmission of the virus. COVID-19 resulted in various challenges in several markets and industries.
- The WHO also revealed that, the pandemic had infected almost 36.6 Mn individuals globally from December 2019 to October 2020.
- Several research organizations and biopharma companies are conducting studies regarding the effects of plasma protease C1-inhibitors while treating systemic abnormalities in patients suffering from COVID‐19. Pharming Group N.V declared that five patients suffering from COVID-19 were treated using RUCONEST at University Hospital Basel, in Switzerland in April 2020, showed encouraging results.
- Encouraging results of the plasma protease C1-inhibitors while treating patients suffering from COVID-19 is estimated to propel growth of the global plasma protease c1-inhibitor treatment market.
Many plasma protease C1-inhibitors have been approved by the U.S. FDA approved for treating Hereditary angioedema C1 esterase inhibitor. This consists of two human pdC1-INH concentrates, nanofiltered C1-INH (nfC1-INH) concentrate and pasteurized, nanofiltered C1-INH (pnfC1-INH) concentrate. Product availability is expected to boost growth of the global plasma protease C1-inhibitor treatment market.
Key Takeaways:
- The global plasma protease C1-inhibitor treatment market over the forecast period, owing to rising clinical trial projects carried out for examining the efficacy of C1-inhibitors in diseases like C1 esterase inhibitor deficiency, hereditary angioedema type I and II and many others.
- Lyophilized segment, among dosage form is estimated to witness significant growth in the global plasma protease C1-inhibitor treatment market over the forecast period, due to rising application in drug administration intravenously, while treating HAE and increasing demand for lyophilized C1 esterase inhibitor drugs.
Key Players:
- Major players active in the global plasma protease C1-inhibitor treatment market are Pharming Technologies B.V., KalVista Pharmaceuticals, Inc, CSL Behring LLC, BioCryst Pharmaceuticals, Takeda Pharmaceutical Company Ltd and Ionis Pharmaceuticals, Inc.
Grab the Offer Mentioned Above Global Outlook and Forecast 2022-2028 @ https://www.coherentmarketinsights.com/promo/buynow/4262
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Dosage
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Impact Analysis
- Market Opportunities
- Collaboration and acquisition
- Market Dynamics
- Plasma Protease C1-inhibitor Treatment Market, Impact of COVID-19 Pandemic
- Post COVID-19 Impact
- COVID-19 Impact on Research and Development Activities
- Demand and Supply Analysis
- Overall impact on manufacturing industry
- Plasma Protease C1-inhibitor Treatment Market, By Drug Type, 2016-2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- C1-inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
- Kallikrein Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
- Selective Bradykinin B2 Receptor Antagonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
- C1-inhibitors
- Introduction
- Plasma Protease C1-inhibitor Treatment Market, By Dosage, 2016-2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- Lyophilized
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
- Lyophilized
- Introduction
- Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel, 2016-2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
- Hospital Pharmacies
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/plasma-protease-c1-inhibitor-treatment-market-3525
About US:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact US:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837